Biotech SF

San Francisco Bay Area biotech stories.

Monday, August 20, 2012

Report: Halcyon Molecular shuts down

Halcyon Molecular Inc., a genetics startup backed by PayPal co-founders Peter Thieland Elon Musk, has reportedly run out of money.
Posted by Unknown at 11:09 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Halcyon Molecular

No comments:

Post a Comment

Newer Post Older Post Home
View mobile version
Subscribe to: Post Comments (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • Pharmacyclics stock sags on disappointing clinical results
    Cancer drug maker Pharmacyclics Inc.’s stock dropped almost 20 percent at one point Monday, after it released disappointing trial data. P...
  • BNBuilders see project growth in health care, colleges
    BNBuilders' David Becker (left) and Sean Truesdale. David Becker and Sean Truesdale, principals at BNBuilders Inc.'s Redwood Cit...
  • Cerus to pursue U.S. approval of plasma safety system
    The Food and Drug Administration will allow Cerus Corp. to submit a premarket application toward approval of its blood safety system, the co...
  • FDA warns Genentech about Boniva ad with Sally Field

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ▼  2012 (486)
    • ►  November (18)
    • ►  October (25)
    • ►  September (56)
    • ▼  August (56)
      • Medivation prostate cancer drug wins FDA approval
      • Targeting Gilead, AIDS Healthcare Foundation seeks...
      • Biotech a possible reuse of Potrero power plant site
      • Mapping the human political genome
      • Bayer submits 'son of Nexavar' cancer drug for FDA...
      • FDA takes Exelixis cancer drug off advisory group ...
      • Medivation to take 2-for-1 split of soaring stock ...
      • Transcept, partner sue to protect new sleep drug f...
      • Daniel O'Day to lead Roche Pharma as Pascal Soriot...
      • FDA extends use of NovaBay wound cleaner, new spra...
      • Pulmonx to start clinical trials for emphysema device
      • FDA approves Gilead's four-in-one HIV pill
      • Fresh off Medicare win, CardioDx lines up $58 mill...
      • Genentech seeks approval of 'armed antibody' targe...
      • Startup genital warts vaccine developer Virolab lo...
      • Theravance, GSK to start approval process for COPD...
      • Gilead battles AIDS group in drug spat
      • VA taps SoundCure device to treat tinnitus
      • Peninsula biotech space feels global pharma blues
      • StartX receives $800K grant to expand nationally
      • Xoma files $100 million mixed shelf offering
      • Xoma lands orphan drug status for eye disease trea...
      • Gilead drops artery disease drug cicletanine after...
      • Report: Halcyon Molecular shuts down
      • One-on-One with Roman Reed, spinal cord injury pat...
      • Relypsa raising $80 million to bring kidney drug t...
      • Former S.F. developer Rosenberg steps up his Alzhe...
      • Fluidigm seeks $52 million from stock offering
      • UCSF hires former Stanford fundraiser for developm...
      • LS9 appoints ex-Genencor boss as chairman
      • Longtime biotech exec Dick Brewer dies from multip...
      • Peter Thiel's Breakout Labs funds artificial meat,...
      • Dynavax hires CFO from PDL Biopharma
      • Prospira PainCare Holdings raises nearly $23 milli...
      • Elan looks to spin Alzheimer's research into South...
      • Varian Medical Systems CEO to step down in September
      • After 10 months, PacBio chief commercial officer M...
      • Biofuel startups target revenue
      • Adynxx glimpses gain from no-pain drugs
      • Genentech's Lucentis approved for diabetic eye dis...
      • Should California economic development go for gold...
      • One-on-One with Talon Therapeutics' Steven Deitcher
      • Growing Nodality strikes drug-development deal wit...
      • CardioDx heart disease test wins Medicare coverage
      • Stanford researchers launch brain cancer study usi...
      • Matt Gardner joins Bay Area Council as chief busin...
      • Pain drug developer Adynxx enrolls first trial
      • Alzheimer's drug bapineuzumab fails late-stage tri...
      • Exelixis shares fall on stock, debt offering news
      • Nile Therapeutics names drug-development veteran a...
      • Gladstone researchers find epilepsy drug that may ...
      • Crescendo tries to convince insurers to pay for it...
      • Solta Medical to raise $14 million in stock sale
      • Gilead inks deal for Indian companies for low-cost...
      • Cal's Energy Biosciences Institute starts move int...
      • Burrill hirings build out life sciences investment...
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ►  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ►  February (77)
    • ►  January (79)
  • ►  2010 (59)
    • ►  December (42)
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews
Simple theme. Powered by Blogger.